IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Milano.
AIR nasce in UNIMI nel 2006 con lo scopo di raccogliere, documentare e conservare le informazioni sulla produzione scientifica dell'Università degli Studi di Milano e costituisce di fatto l'Anagrafe della ricerca dell'Ateneo.
EnglishIntroduction: Gene fusions are strong driver alterations in various cancers, increasingly diagnosed with multiple testing techniques. ROS1 fusions can be found in 1-2% of non-small cell lung cancer (NSCLC) and several tyrosine kinase inhibitors (TKIs) have been tested in this oncogene-driven disease. NTRK fusions are characteristic of a few rare types of cancer, also infrequently seen in some common cancers including NSCLC. Entrectinib is a newer ROS1 and NTRK inhibitor developed across different tumor types harboring rearrangements in these genes. Entrectinib was granted FDA accelerated approval in August 2019 for the treatment of ROS1+ NSCLC and NTRK-driven solid tumors. Areas covered: This review covers the mechanism of action, safety, and efficacy of entrectinib in patients with metastatic NSCLC. Expert opinion: Entrectinib is an orally bioavailable TKI of TrkA, TrkB, TrkC, and ROS1, with the ability to cross the blood-brain barrier. Entrectinib was effective and well-tolerated in patients harboring ROS1- or NTRK-rearranged NSCLC treated within phase I and II studies. Entrectinib appears to be the most appropriate treatment choice for TKIs-naïve patients, especially in those presenting brain metastasis. Conversely, in case of systemic progression with the evidence of acquired resistance mutations in ROS1 or Trk proteins, a sequential therapy with entrectinib could not be successful.
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy / A. Sartore Bianchi, E.G. Pizzutilo, G. Marrapese, F. Tosi, G. Cerea, S. Siena. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 20:5(2020 May 03), pp. 333-341.
| Titolo: | Entrectinib for the treatment of metastatic NSCLC: safety and efficacy |
| Autori: | PIZZUTILO, ELIO GREGORY (Secondo) CEREA, GIULIO (Penultimo) SIENA, SALVATORE (Ultimo) |
| Parole Chiave: | Entrectinib; lung cancer; NSCLC; NTRK; ROS1; Rozlytrek; targeted therapy |
| Settore Scientifico Disciplinare: | Settore MED/06 - Oncologia Medica |
| Data di pubblicazione: | 3-mag-2020 |
| Rivista: | |
| Tipologia: | Article (author) |
| Data ahead of print / Data di stampa: | apr-2020 |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1080/14737140.2020.1747439 |
| Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| sartore-bianchi entrectinib NSCLC ERAT 2020.pdf | Post-print, accepted manuscript ecc. (versione accettata dall'editore) | Embargo: 01/04/2021 Richiedi una copia |
Copyright © 2020